DELAYED INNOVATION
Why are overall timelines moving in the wrong direction?

The most recent Time and Cost to Market report from AgbioInvestor indicates the following significant trends:

TIME-TO-MARKET HAS GONE UP
The mean time to bring a new GM trait to commercialisation has increased 26% since 2012.

COST-TO-MARKET HAS COME DOWN
Overall costs have fallen by $21M, driven primarily by greater efficiency in the trait discovery phase.

Delivering a new GM trait to market requires an average investment of:

16.5 YEARS
More than half that time – 8.5 years – is spent on regulatory approval alone.

$115 MILLION
The regulatory phase accounts for 37.6% of total costs.

WHAT’S TAKING SO LONG?

The regulatory phase accounts for 37.6% of the total cost – but takes up 51.1% of the time.

HOW DO WE FIX IT?

In nearly all other markets, as regulators become more familiar with a technology, the time to approval decreases. This trend is reversed for GM crops in most jurisdictions.

A MORE HARMONIZED GLOBAL REGULATORY FRAMEWORK WOULD:

- Improve time to market
- Promote innovation
- And ultimately help growers and consumers alike

UNDER DEVELOPER CONTROL
Technology developers have improved and become more efficient in the discovery and optimization phases.

BEYOND DEVELOPER CONTROL
The regulatory phase has increased in time by 140% since the 2008-2012 study.

Source: AgbioInvestor 2022/CropLife International Members Survey conducted by AgbioInvestor and reflects the input of four global brands for the period 2017-2022. Previous study results are from a similar survey conducted for the period 2008-2012.
**DELAYED INNOVATION**
Why are overall timelines moving in the wrong direction?

### INCREASING REGULATORY TIMELINES

<table>
<thead>
<tr>
<th>Patent Lifetime</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------</td>
</tr>
<tr>
<td>13.1 years (2008-2012)</td>
<td>16.5 years (2017-2022)</td>
</tr>
</tbody>
</table>

### Total Costs Attributed to Each Development Category

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008-2012</td>
<td>$136 million</td>
</tr>
<tr>
<td>2017-2022</td>
<td>$115 million</td>
</tr>
</tbody>
</table>

**2008-2012**

- Discovery (Early, Late): $31.0M
- Genetic Event Construction and Testing: $43.2M
- Regulatory: $69.9M

**2017-2022**

- Discovery (Early, Late): $7.6M
- Genetic Event Construction and Testing: $43.2M
- Regulatory: $64.2M

**Comparing to 2012, time spent in discovery has decreased from 23% to 13.3%.**

**Time spent in construction and testing has dropped from 40.2% to 35.6%.**

**It’s clear that innovation is needed** to achieve zero hunger, improve food security, and adapt to and mitigate climate change. Developers have tools and resources that can ease the burden on the world’s farmers and help them farm sustainably and productively, but those in the food value chain must have access to these innovations in a timely manner. Global challenges like food security and climate change depend on it.

Source: AgBioInvestor 2022/CropLife International Members Survey conducted by AgBioInvestor and reflects the input of four global brands for the period 2017–2022.

Previous study results are from a similar survey conducted for the period 2008–2012.